Expression of ST2L on CD8+ T cells represents a mechanism regulating IL-33 bioactivity on a cellular level also in the context of tumor immunity, although the function of IL-33 in tumor immunity is currently controversially discussed. The gene discussed is CD8A; the disease is neoplasm.